Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Open Journal of Cardiology & Heart Diseases

Anaemia, Dysfunctional Mitochondria and Heart Failure: Are we Able to Connect These Foes by Understanding Their Pathophysiology?

  • Open or Close Venu Gopal Jonnalagadda1*, Kanchan Choudhary2 and Vijay Kranti Matety1

    1Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, India

    2Department of Pharmacology & Toxicology, Bhupal Nobles’ Institute of Pharmaceutical Sciences, India

    *Corresponding author: Venu Gopal Jonnalagadda, Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, C/O NETES Institute of Technology & Science, NH-37, Shantipur, Parli Part, Mirza, Assam-781125, India

Submission: April 09, 2018; Published: April 18, 2018

DOI: 10.31031/OJCHD.2018.01.000524

ISSN: 2578-0204
Volume1 Issue5

Abstract

Despite major advances in the cardiovascular medicine in the 20th century, heart failure (HF) is an exceptional with estimated prevalence of >37.7 million globally caused by secondary aetiologies ultimately affecting their quality of life, including dyspnoea, poor exercise tolerance, fatigue, and fluid retention. Currently, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists, β blockers, angiotensin receptor blocker neprilysin inhibitors (ARNIs) and advanced device therapies have been administered to patients with reduced ejection fraction (EF) [1].

Get access to the full text of this article